Produced by the Australian Institute of Health and Wellbeing (AIHW), this report quantifies the level of suicide among serving and ex-serving Australian Defence Force (ADF) personnel and identifies factors that may be associated with suicide risk. Analysis in the summary report examined each service-related characteristic associated with risk of suicide individually.

The Department of Veterans' Affairs commissioned the Australian Institute of Family Studies (AIFS) to identify and synthesise existing research on older veterans, and their families’ experiences and needs in aged care. The project was commissioned to inform any future improvements to the way aged care is delivered to veterans and to identify gaps in understanding of the needs of older veterans and their families in aged care settings.

DVA commissioned Gallipoli Medical Research Foundation (GMRF) to undertake a rolling Rapid Evidence Assessment (REA) of emerging and adjunct treatments for post-traumatic stress disorder (PTSD) and common mental health conditions affecting veterans. The emerging treatments were psychedelic interventions (i.e., ketamine; methylenedioxymethamphetamine, MDMA; lysergic acid diethylamide, LSD; psilocybin; and dimethyltryptamine, DMT, including ayahuasca), medicinal cannabis, d-cycloserine (DCS), stellate ganglion block (SGB), and transcranial magnetic stimulation (TMS, including theta-burst stimulation, TBS). The initial REA was delivered in a tranche of seven individual reports in 2022. Four update reports were contracted at 6-monthly intervals to incorporate the most up-to-date information from newly published studies. The goal of the REA was to provide an evidence base to develop a flexible, yet robust, decision-making process that allows DVA to assess emerging treatments for veterans who have not responded to evidence-based treatments.

DVA commissioned Gallipoli Medical Research Foundation (GMRF) to undertake a rolling Rapid Evidence Assessment (REA) of emerging and adjunct treatments for post-traumatic stress disorder (PTSD) and common mental health conditions affecting veterans. The emerging treatments were psychedelic interventions (i.e., ketamine; methylenedioxymethamphetamine, MDMA; lysergic acid diethylamide, LSD; psilocybin; and dimethyltryptamine, DMT, including ayahuasca), medicinal cannabis, d-cycloserine (DCS), stellate ganglion block (SGB), and transcranial magnetic stimulation (TMS, including theta burst stimulation, TBS). The initial REA was delivered in a tranche of seven individual reports in 2022. Four update reports were contracted at 6-monthly intervals to incorporate the most up-to-date information from newly published studies. The goal of the REA was to provide an evidence base to develop a flexible, yet robust, decision-making process that allows DVA to assess emerging treatments for veterans who have not responded to evidence-based treatments.

DVA commissioned Gallipoli Medical Research Foundation (GMRF) to undertake a rolling Rapid Evidence Assessment (REA) of emerging and adjunct treatments for post-traumatic stress disorder (PTSD) and common mental health conditions affecting veterans. The emerging treatments were psychedelic interventions (i.e., ketamine; methylenedioxymethamphetamine, MDMA; lysergic acid diethylamide, LSD; psilocybin; and dimethyltryptamine, DMT, including ayahuasca), medicinal cannabis, d-cycloserine (DCS), stellate ganglion block (SGB), and transcranial magnetic stimulation (TMS, including theta burst stimulation, TBS). The initial REA was delivered in a tranche of seven individual reports in 2022. Four update reports were contracted at 6-monthly intervals to incorporate the most up-to-date information from newly published studies. The goal of the REA was to provide an evidence base to develop a flexible, yet robust, decision-making process that allows DVA to assess emerging treatments for veterans who have not responded to evidence-based treatments.

DVA commissioned Gallipoli Medical Research Foundation (GMRF) to undertake a rolling Rapid Evidence Assessment (REA) of emerging and adjunct treatments for post-traumatic stress disorder (PTSD) and common mental health conditions affecting veterans. The emerging treatments were psychedelic interventions (i.e., ketamine; methylenedioxymethamphetamine, MDMA; lysergic acid diethylamide, LSD; psilocybin; and dimethyltryptamine, DMT, including ayahuasca), medicinal cannabis, d-cycloserine (DCS), stellate ganglion block (SGB), and transcranial magnetic stimulation (TMS, including theta burst stimulation, TBS). The initial REA was delivered in a tranche of seven individual reports in 2022. Four update reports were contracted at 6-monthly intervals to incorporate the most up-to-date information from newly published studies. The goal of the REA was to provide an evidence base to develop a flexible, yet robust, decision-making process that allows DVA to assess emerging treatments for veterans who have not responded to evidence-based treatments.

In Australian-first research, the Department of Veterans’ Affairs (DVA) commissioned Phoenix Australia – Centre for Posttraumatic Mental Health to examine the rates of intimate partner violence among current- and ex-serving Australian Defence Force (ADF) personnel, using data collected in 2015 from a large-scale study of current (at the time) and recently (then) transitioned ADF personnel and their families.

For the purposes of this research, the Transition and Wellbeing Research Programme data was used to:

• examine the rates of intimate partner violence within the Australian veteran community;
• identify vulnerable groups; and
• provide an understanding of the implications of intimate partner violence on help-seeking and service utilisation.

Findings from the study suggest an elevated number of veteran families having experienced IPV, identifying them as a vulnerable cohort. 

Future application

The findings highlight opportunities for continued action to address intimate partner violence in the veteran community, a national priority for the Australian Government and the DVA.

The research will inform and enhance work already underway, including DVA’s Family and Domestic Violence Strategy 2020-2025, the National Plan to End Violence Against Women and Children 2022-2032, and the Defence Strategy for Preventing and Responding to Family and Domestic Violence 2023-2028.

How can we support you

If you, or someone you know, is at risk of violence, call Open Arms – Veterans & Families Counselling on 1800 011 046. In an emergency, call triple zero (000).

The aim of this project was to review the literature in relation to how moral injury is conceptualised, models of moral injury, linkages between moral injury and common mental health issues, and the effectiveness of moral injury interventions in veteran and military populations.

In order to answer these questions, a narrative literature review and a REA were conducted.

DVA funded a four-year research trial through La Trobe University, in partnership with the Centre for Service and Therapy Dogs Australia (CSTDA), to provide detailed guidance and evidence to support best practice in the use of psychiatric assistance dogs for veterans with PTSD. Evolution Research were engaged to conduct the independent evaluation of the Trial.

The Trial’s objective was to train, allocate and monitor assistance dogs as an adjunct to evidence-based treatment for veterans with PTSD, to determine the following outcomes: 

• the clinical utility of using specifically-trained assistance dogs as an adjunct to evidence-based treatment for PTSD in a veteran population; 
• the benefits of specifically-trained assistance dogs used by veterans with PTSD in decreasing related caregiver burden; and 
• the key barriers and enablers for a possible future broader implementation of an assistance dog program of the type conducted under the Trial. 

The Trial evaluated the life experiences of 20 veterans with a diagnosis of PTSD through their journey of being paired with a specifically trained assistance dog. The veteran’s journey commenced at the time of recruitment and initial assessment, involvement in a comprehensive training program and matching of a dog to meet their unique needs. Following completion of the training program and preparedness the veteran received handover of their dog to live with them full time. 

Of the 20 veterans recruited, a total of 17 completed the Trial on 30 June 2022 and continue to live with their dog. The three veterans that did not complete the Trial voluntarily withdrew due to personal circumstances. Exit interviews to capture their experiences were conducted and noted in the evaluation report.

The Trial was successful in meeting its objectives and the evaluation findings and recommendations are being considered by DVA’s Psychiatric Assistance Dog Program for opportunities to enhance delivery of the Program.

The following comments were captured from trial participants and support persons during the evaluation and are included in the report

“I can’t express enough how much this program has been of benefit. I have little doubt that my service dog has saved my life” – Veteran John

“My wife says she “has the old me back”, my parents have commented on the change the dog has had on me, with comments such as…”we haven’t seen this bloke in 20yrs” – Veteran Brian

“I have more freedoms to do things that I like without feeling guilty or worrying about my husband. I cannot thank them enough for their dedication, patience and care shown to not only my husband but our entire family” - Support Person Jenny

“Conversations about difficult subjects have become approachable and easier. Our communication has improved in all aspects of our life” – Support Person Susan

The key findings of the Middle East Area of Operations (MEAO) Census and Prospective Health Studies were launched by the Chief of the Defence Force on 8 August 2013.  These studies are part of the Military Health Outcomes Program (MilHOP), a significant body of research commissioned by the Department of Defence to determine the impact of operational deployment on the health and wellbeing of service men and women.

The results suggest that ADF members deployed to the MEAO are generally physically and mentally healthy.  However, members repeatedly exposed to traumatic experiences, either at home or on deployment, are more likely to develop mental health concerns.

DVA continues to seek opportunities to improve and evolve service models to meet the changing needs of clients and will use the studies’ findings to help inform future research priorities within DVA’s Strategic Research model.

Further information on the studies and access to the reports is available on the Department of Defence’s Military Health Outcomes Program webpage